A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Dry Eye Disease

In brief

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.

Key facts

Study ID
NCT06225973
Run by
Telios Pharma, Inc.
People needed
880
Starts
2024-02-06
Expected to finish
2024-12-01
Last updated by the study team
2024-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.